alexa TREATMENT OF HUMAN PANCREATIC BETA CELLS WITH A COMBINATION OF GAMMA-AMINOBUTYRIC ACID (GABA) AND GLP-1 AMELIORATES CELL SURVIVAL AND PROLIFERATION
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

18th European Diabetes Congress
July 17-18, 2017|Lisbon, Portugal

Gerald J Prud'homme
St. Michael's Hospital, University of Toronto, Canada
Keynote: J Diabetes Metab
DOI: 10.4172/2155-6156-C1-065
Abstract
An effective therapy for type 1 diabetes (T1D) requires the protection of pancreatic beta cells against autoimmunity (immunosuppression and/or anti-inflammatory activity) and beta-cell proliferation or regeneration. No current treatment achieves both goals in a clinical setting. The incretin hormone GLP-1 is effective in the treatment of type 2 diabetes (T2D), but not T1D. Recent studies by us and others have shown that GABA protects beta cells against autoimmune injury and induces their regeneration in mice. In this study, we investigated the effects of these drugs on human islets cells, and compared their response to rodent insulinoma cell lines. We found that GABA increases SIRT1 and Klotho (mRNA and protein), and prevents apoptosis induced by high glucose levels or inflammatory cytokines. Importantly, both Klotho and SIRT1 inhibit the activation of NF-kB. The NF-kB inflammatory pathway provokes beta-cell apoptosis, such that its blockade is protective. We show that a GLP-1 receptor (GLP-1R) agonistic drug ameliorates the effects of GABA in some assays. However, we observed that a GLP-1R agonist does not stimulate human beta-cell proliferation, whereas GABA does promote proliferation. We conclude that GABA, especially when combined with GLP-1, effectively protects human beta islet cells against glucotoxicity and other injuries, and that GABA (but not GLP-1) stimulates their proliferation. These observations suggest that GABA+GLP-1 therapy will be effective in human T1D, due to a combination of anti-apoptotic, anti-inflammatory and proliferative/regenerative effects.
Biography

Gerald J Prud'homme is a Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, and Clinician-Scientist at St. Michael’s Hospital, Toronto. He received his MD degree from the University of Ottawa, Canada (1977) and subsequently specialized in Pathology. He is a Research Fellow at the Institute of Immunology, University of Toronto, the Scripps Research Institute and the McGill Cancer Centre (McGill University, Montreal). Subsequently (1985-2002), he worked as a Scientist and Pathologist in the Department of Pathology, McGill University. His main research interests are in the areas of immunotherapy of autoimmune diseases and cancer therapy.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords